Autoimmune Disease Treatments: Current and Emerging Options

#1

I noticed we don’t seem to have a dedicated thread focused on autoimmune conditions in general, so I thought it would be useful to start one.

This thread is for sharing and discussing promising existing, emerging, and future treatments for autoimmune diseases of all kinds, including both mainstream therapies and credible pipeline developments.

Examples could include:

New biologics and targeted small molecules

CAR-T / cell therapies for autoimmune disease

Immune tolerance approaches

Repurposed drugs with evidence

Lifestyle or adjunct interventions with solid data

Treatments in clinical trials worth watching

Conditions can include psoriasis, rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, asthma with autoimmune/inflammatory components, and others.

The goal is to build a useful watchlist of therapies that may improve quality of life, reduce long-term damage, and potentially support healthspan for people dealing with immune dysfunction.

#2

https://meddatax.com/news/kyverna-therapeutics-car-t-clinical-and-financial-update

GPT summary of relevance to longevity field:

Autoimmune CAR-T may be one of the more underrated developments relevant to longevity.

This is not a lifespan therapy today, but it is a major proof-of-concept that we may be able to deeply reset dysfunctional immune states rather than endlessly suppress symptoms with chronic drugs.

Kyverna’s positive data in myasthenia gravis, plus activity across stiff person syndrome, RA, MS, etc., suggests autoimmune CAR-T could become a platform approach.

Why longevity people should care:

Chronic autoimmune/inflammatory disease accelerates damage, frailty, vascular risk, and biological aging

Long-term steroids/immunosuppressants carry major downstream costs

Durable remission after a one-time cellular therapy could preserve healthspan

Success here helps build cell therapy infrastructure later usable for immune rejuvenation, fibrosis, senescence targeting, and regenerative medicine

Future possible targets could include severe refractory psoriasis, psoriatic arthritis, inflammatory bowel disease, lupus, and selected severe immune-driven asthma phenotypes.

Near-term reality:

Likely reserved for severe cases first

Expensive

Specialist-center treatment

Safety still key

Big picture: today it’s autoimmune medicine. Tomorrow it may be a stepping stone toward precision reprogramming of aged or pathological immune systems, which is highly relevant to healthspan extension.